GENERAL
Aurobindo Pharma Bets On Specialty Drugs, Biosimilars For Next Expansion
Aurobindo Pharma Ltd is doubling down on high-value specialty medicines, biosimilars and complex formulations while strengthening its manufacturing footprint and supply chain resilience as it charts its next phase of global growth. In his message to shareholders in the company’s Annual Report 2026, Vice Chairman & Managing Director K. Nithyananda Reddy said the company will […]
CW Bureau
·
Aug 4, 2026
GENERAL
Biocon Launches Interchangeable Eye Drug Biosimilar Yesafili In US Market
Biocon Ltd has commercially launched Yesafili, its interchangeable biosimilar to blockbuster eye drug Eylea (aflibercept) 2 mg, in the United States, marking a significant expansion of its ophthalmology portfolio in the world’s largest pharmaceutical market. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of various retinal disorders, including age-related macular […]
CW Bureau
·
Aug 3, 2026
GENERAL
Sun Pharma Receives Organon Shareholders Nod For $11.75-Bn Buy
Leading global pharmaceutical company Sun Pharmaceutical Industries Ltd has received shareholder approval from Organon & Co. for its proposed acquisition. The approval marks a key milestone towards completion of the transaction. Following the deal, Organon will become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA Inc., an indirect wholly owned subsidiary of Sun Pharma. […]
CW Bureau
·
Jul 24, 2026
GENERAL
Lupin Banks On Biosimilars, Specialty Medicines To Power Next Expansion
Lupin Ltd is stepping up its focus on biosimilars, specialty medicines, complex generics and artificial intelligence (AI) as it builds the next phase of its growth strategy, according to Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta in a joint message to shareholders in the company’s Annual Report 2026. The leadership said years […]
CW Bureau
·
Jul 14, 2026
GENERAL
Indian Pharma Firms To Gain Up To $5 Bn From Global Patent Cliff: CareEdge
Indian pharmaceutical companies are poised to benefit from a major global patent expiry cycle, with drugs generating nearly $142 billion in sales in CY25 set to lose exclusivity between 2026 and 2030, according to a report by CareEdge Ratings. The report estimates that the upcoming patent cliff could create a market opportunity of over $30-40 […]
CW Bureau
·
Jun 19, 2026
GENERAL
Cipla Bets On Innovation, Biosimilars And AI To Drive Next Phase Of Growth
Cipla Ltd, the Mumbai-headquartered global pharmaceutical major, is stepping up investments in innovation, artificial intelligence, biosimilars and strategic acquisitions as it looks to strengthen its position across key global markets and build a future-ready organisation. India will remain a key growth driver, with the company focusing on therapy areas including respiratory, cardiology, diabetology, urology, oncology, […]
CW Bureau
·
Jun 2, 2026
GENERAL
Sun Pharmaceuticals To Acquire Organon In $11.75-Bn All-Cash Deal
Sun Pharmaceutical Industries Ltd, leading specialty generics company, will acquire Organon at $14 per share in an all-cash transaction, valuing the company at an enterprise value of $11.75 billion, funded through internal accruals and borrowings. The transaction will be executed through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the […]
CW Bureau
·
Apr 27, 2026
